Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease

Chakradhari Inampudi¹, Paulino Alvarez¹, Rabea Asleh² and Alexandros Briasoulis¹*

¹Division of Cardiovascular Diseases, Section of Heart Failure and Transplant, University of Iowa Hospitals and Clinics, Iowa City, IA, USA; ²Department of Cardiovascular Diseases, Mayo Clinic, Rochester MN, USA

Abstract: Background: Several risk factors including Ischemic heart disease, uncontrolled hypertension, high output Heart Failure (HF) from shunting through vascular hemodialysis access, and anemia, contribute to development of HF in patients with End-stage Renal Disease (ESRD). Guideline-directed medical and device therapy for Heart Failure with Reduced Ejection Fraction (HFrEF) has not been extensively studied and may have limited safety and efficacy in patients with ESRD.

Results: Maintenance of interdialytic and intradialytic euolemia is a key component of HF management in these patients but often difficult to achieve. Beta-blockers, especially carvedilol which is poorly dialyzed is associated with cardiovascular benefit in this population. Despite paucity of data, Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotensin II Receptor Blockers (ARBs) when appropriately adjusted by dose and with close monitoring of serum potassium can also be administered to these patients who tolerate beta-blockers. Mineralocorticoid receptors in patients with HFrEF and ESRD have been shown to reduce mortality in a large randomized controlled trial without any significantly increased risk of hyperkalemia. Implantable Cardiac-defibrillators (ICDs) should be considered for primary prevention of sudden cardiac death in patients with HFrEF and ESRD who meet the implant indications. Furthermore in anemic iron-deficient patients, intravenous iron infusion may improve functional status. Finally, mechanical circulatory support with left-ventricular assist devices may be related to increased mortality risk and the presence of ESRD poses a relative contraindication to further evaluation of these devices.

Keywords: Therapeutic approach, heart failure, end stage renal disease, hemodialysis, beta-blockers, ESRD.

1. INTRODUCTION

Heart Failure with Reduced Ejection Fraction (HFrEF) and End-stage Renal Disease (ESRD) are global epidemics and are also leading causes of morbidity and mortality [1-4]. Despite current advances in medical and device-based therapies, the long-term prognosis of patients with heart failure continues to be poor [5]. Studies have shown that in addition to higher mortality from progressive pump failure and sudden cardiac death, heart failure patients suffer from multiple comorbidities that elevate their morbidity and mortality [6-8]. Among the co-morbidities, a large proportion of patients have varying degrees of renal dysfunction ranging from mild chronic kidney disease to ESRD requiring dialysis. Previous studies have shown that patients with ESRD are at heightened risk for varying cardiovascular (CV) and cerebrovascular events. CV mortality and morbidity are about 2 to 10 times that of general population with normal renal function. Among patients on hemodialysis (HD), heart disease is the leading cause of mortality [9]. It is estimated that patients on dialysis have 8% higher mortality than the general population and cardiovascular mortality is estimated to be 43% [10]. Approximately 70% of patients with ESRD on HD also have HFrEF [11]. In addition, in patients with ESRD, heart failure is a common manifestation with nearly 30-40% patients on HD shown to have prevalent heart failure [12-15]. In ARIC study [16], the presence of HF at the time of dialysis initiation, both hemodialysis (HD) and Peritoneal Dialysis (PD), is associated with higher short and long term mortality. The median survival is estimated to be 36 months. HFrEF and ESRD share common risk factors in the form of diabetes mellitus, hypertension, coronary artery disease, obesity, tobacco use etc. Furthermore these 2 highly co-morbid conditions utilize significant amount of health care resources imposing significant burden on the health care system. Available data on the use of optimal medical therapy in patients with coexistent HFrEF and ESRD on dialysis is limited to post hoc analysis with very few prospective trials. Despite lack of evidence, the National Kidney Foundation Kidney Disease Outcome Quality Initiative group recommend medical therapy involving the use of Beta Blockers (BB), Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin Receptor Blockers (ARB) and Mineralocorti-
to improve outcomes like reduction in hospitalizations and mortality [20-23].

In this current review, we sought to identify the existing literature with regards to use of current guideline directed medical therapy in patients with HFrEF and ESRD.

2. BETA-BLOCKERS AND ESRD

Several RCT have clearly established the beneficial effects of the beta-blockers in patients with chronic systolic heart failure and normal or mildly reduced renal function. Earlier studies have shown that in patients on dialysis, high plasma norepinephrine levels predict adverse cardiovascular events and mortality [24] but limited evidence exists about the safety and efficacy of these agents in patients with HFrEF and ESRD.

To date, only one randomized control trial (RCT) has examined the effects of beta-blockers in such patient population. The study examined 114 patients on dialysis and with chronic systolic heart failure with LVEF < than 30% and NYHA FC II-III, for 12 months. It has been noted that the use of Carvedilol is associated with significant improvement in LVEF and NYHA class [25] and reduction in all-cause mortality [22] (51.7% mortality rate in the carvedilol group versus 73.2% in the placebo group; P < 0.01) that was noted on extended follow up for about 24 months. There was also a trend toward reduction in sudden cardiac death and pump failure deaths [HR] 0.76; P = 0.12 although this was not statistically significant. A statistically significantly lower rate of CV mortality (29.3% versus 67.9%; P < 0.0001) and all-cause hospital admission (34.5% versus 58.9%; P < 0.005) was also noted in the carvedilol group than in the placebo group. Further, the study also showed that in recipients of carvedilol, there was a lower rate of fatal myocardial infarctions, fatal strokes, and hospital admissions for worsening HF. There was also a significant improvement in LVEF as demonstrated by the 2-year echocardiographic data (Table 1).

The dialyzability of beta-blockers may be associated with differential effects on outcomes. In a retrospective cohort of 6588 patients on hemodialysis, beta blockers that

Table 1. Representative clinical trials of heart failure with reduced ejection fraction and end stage renal disease: Study design and outcome.

| Trial  | No of Patients | Dialytic Modality (HD: Hemodialysis s, PD: Peritoneal Dialysis) | Presence of HF (LVEF < 45%) (% of Patients) | Design | Intervention | Control | Follow Up | Outcome |
|--------|----------------|---------------------------------------------------------------|---------------------------------------------|-------|--------------|---------|----------|---------|
| Cice 2001 | 114 | HD | 100 | Randomized, double-blind placebo controlled | Carvedilol (25 mg bid or maximum tolerated dose) | Placebo | 12 months | Carvedilol improved LVEF relative to placebo (26.3% to 34.8%, p < 0.05) and LV end-diastolic volume (100 ml/m² to 94 ml/m² P < 0.05) and LV end-Systolic volume (74 ml/m² to 62 ml/m² P < 0.05) |
| Cice 2003 | 114 | HD | 100 | Randomized, double-blind placebo controlled | Carvedilol (25 mg bid or maximum tolerated dose) | Placebo | 24 months | Carvedilol reduced all-cause mortality (HR, 0.51; 95% CI, 0.32 to 0.82; P < 0.01) and cardiovascular mortality (HR, 0.32; 95% CI, 0.18 to 0.57; p < 0.0001) |
| Cice 2010 | 332 | HD | 100 | Randomized, double-blind placebo controlled | Telmisartan (target dose 80 mg/day) | Placebo | 36 months | Telmisartan reduced all-cause mortality (35.1% vs. 54.4%; P < 0.0001), CV death (30.3% vs. 43.7%; P < 0.0001) and hospital admission for CHF (33.9% vs. 55.1%; P < 0.0001) |
| Taheri 2009 | 16 | HD | 100 | Randomized, double-blind placebo controlled | Spironolactone (25 mg 3x/wk post-HD) | Placebo | 6 months | Spironolactone improved LVEF relative to placebo (LVEF: 6.2 ± 1.6 vs. 0.83 ± 4.9%, P=0.05) |
| Taheri 2012 | 18 | PD | 100 | Randomized, double-blind placebo controlled | Spironolactone (25 mg every other day) | Placebo | 6 months | Spironolactone improved LVEF relative to placebo (25.7 ± 7.3 vs. 33.3 ± 7.8%, P= 0.002) |
are poorly dialyzed such as bisoprolol or carvedilol provide a survival benefit compared with easily dialyzed beta blockers such as metoprolol [26]. More recently, Tang et al. have shown that in patients with heart failure and receiving long term hemodialysis, beta-blockers are associated with improved survival [27]. Overall, beta blockers appear safe and efficacious in these patients if initiated at low doses and adjusted carefully to avoid hypotensive episodes.

3. ACEI AND ESRD

ACE inhibitors and their beneficial effects in patients with HFrEF have been examined in multiple randomized clinical trials. ACE inhibitor use is associated with improved survival in patients with HFrEF by their beneficial effects on reducing ventricular remodeling [28] and also by their effects on left ventricular ejection fraction as shown in clinical trials [29, 30]. In addition some of the survival benefit might also be due to slower progression of the underlying disease in patient subset with advanced chronic kidney disease [31-36].

Because of their significant beneficial effects, current guidelines recommend them as class I agents. However, the data supporting their role in dialysis patients is sparse. In a double blind placebo-controlled RCT in 397 HD patients with LVH [37], fosinopril failed to show any significant effect on a composite CV end-point. Furthermore, the study was underpowered to estimate survival benefit with fosinopril. Among HD patients who participated in the HEMO study, using proportional hazards regression and a propensity score analysis, Chang et al. evaluated the effects of ACE use [38]. The authors found no significant associations between ACEI use and mortality, CV hospitalization, and other CV outcomes. Surprisingly, in the proportional hazards model, ACEI use was even associated with a higher risk of HF hospitalization. In a retrospective analysis of the data from the Minnesota Heart Survey [39], dialysis patients hospitalized with HF had no benefit in either short-term (30 days) or long-term (1 year) survival, from use of ACEI or ARB treatment. Retrospective analysis conducted by Berger et al. using Cooperative cardiovascular project showed that in a sample of 1025 patients receiving hemodialysis, ACEI use was associated with significant mortality reduction (17.3 vs. 33.4%, P value: < 0.001) even after adjustment for baseline demographic risk factors and clinical risk factors (RR 0.58 (0.42-77) [40]. Studies conducted by Efrati S et al. [41] and McCullough PA et al. [42] confered similar beneficial effects. At this time, review of the literature suggests some beneficial effect with ACE inhibitors in ESRD patients, but much of the evidence comes from observational data and registry analysis which by itself is not sufficient to assess the safety and efficacy of the ACE inhibitor use in the proposed patient population. Lack of available data highlights the critical need for a large-scale clinical trial, to determine if a statistically significant reduction in mortality can be achieved in this patient population who are at high risk of adverse primary and secondary cardiovascular outcomes.

4. ANGIOTENSION RECEPTOR BLOCKER (ARB) AND HD

A single RCT has been conducted so far using ARBs in ESRD patients. In a multicenter Italian trial [43] 332 HD patients with HF (NYHA II-III; LVEF ≤ 40%), who were randomized to telmisartan or placebo, in addition to ACEI therapy, telmisartan showed statistically significantly reduction in all-cause mortality (35.1% versus 54.4%; P < 0.001), CV death (30.3% versus 43.7%; P < 0.001), and hospital admission for HF (33.9% versus 55.1%; P < 0.0001). With regards to safety, adverse effects, mainly in the form of hypotension, occurred in 16.3% of the telmisartan group versus 10.7% in the placebo group (Table 1).

5. MINERALOCORTICOID RECEPTOR ANTAGONISTS (MRA) AND ESRD

Multiple animal and human studies have shown that despite the Renin-angiotensin-aldosterone blockade, aldosterone breakthrough leads to progression of renal and cardiac disease supporting the role of MRA in this patient population [44-49]. Although in general, serum potassium levels rise after MRA administration, life-threatening or clinically meaningful hyperkalemia may be less of an issue in the ESRD patients, as potassium levels are regulated by the hemodialysis treatments and not by the renal tubule. In addition, other metabolic derangements like hypercalcemia may play a protective role because of the membrane stabilizing action of the calcium. Racial differences also play a role with ability of the African American patients to better tolerate hyperkalemia due to lower dietary intake, high rates of unprovoked hypokalemia, lower renin activity and differences in urinary potassium excretion.

In Iran, Taheri et al. conducted a small double-blind RCT of spironolactone 25 mg/day versus placebo, in addition to an ACEI or an ARB, in 16 HD patients with HFrEF (NYHA classes III-IV and LVEF < 45%). After 6 months of treatment, significant increase in mean LVEF with decrease in mean LV mass was noted in the spironolactone group than in the placebo group. The incidence of hyperkalemia was unchanged in both groups [50]. In another study with an identical design conducted by the same research team, a significant increase in LVEF (25.7 ± 7.3 vs. 33.3 ± 7.8, P = 0.002) in the spironolactone group (25 mg taking every other day) but not in the placebo group and a non-significant increase in serum potassium in both groups was noted in 18 continuous ambulatory peritoneal dialysis (CAPD) patients with HFrEF (NYHA classes III-IV and LVEF < 45%) [51]. Chua et al. recently reviewed 6 RCTs that evaluated the safety of low-dose spironolactone in Hemodialysis (HD) patients of which, about 50% were on background therapy with ACEI or ARB therapy. The authors found that the incidence of hyperkalemia with spironolactone treatment was similar to that in control groups; however, all these studies involved small populations of compliant subjects, who were at low risk for hyperkalemia [52]. At this time, safety and positive effect of MRN in patients on dialysis remain unclear. Currently, the ALCHEMIST trial designed to establish the effects of the spironolactone vs placebo on major cardiovascular events in chronic hemodialysis patients (NCT01848639) and HFrEF (LVEF < 40%) is recruiting subjects at this time.
6. DIGOXIN

Digoxin use in patients with HF and ESRD was analyzed by Chan et al. for survival benefit in a retrospective cohort, using covariate- and propensity-score-adjusted Cox models. They noted that Digoxin use was associated with a 28% increased risk for death in over 120,000 patients on incident HD. Increasing serum digoxin concentration was also significantly associated with mortality, most markedly in patients with lower pre-dialysis serum potassium [53].

7. NEW DRUGS

Ivabradine, an inhibitor of the I1-ionic current, has not been studied in patients with estimated glomerular filtration rate (eGFR) below 15 ml per minute per 1.73 m2 of body-surface area [54]. Use of Ivabradine in patients with estimated glomerular filtration rate (eGFR) below 15 ml per minute per 1.73 m2 of body-surface area is limited. In CARVIVA HF trial, Ivabradine 7.5 mg bid was tested in hemodialysis patients with heart failure. Approximately 46% of patients were noted to have systolic and 54% to have diastolic HF. Patients on ivabradine alone or in combination with carvedilol demonstrated better exercise tolerance and quality of life compared with carvedilol alone [55-57]. Due to sample size and lack of studies with hard outcomes such as HF mortality and hospitalization, the use of Ivabradine is not encouraged in patients with HFrEF and ESRD until further evidence is available.

Sacubitril-Valsartan otherwise known as LCZ696, proven to be effective in reducing cardiovascular death or heart failure hospitalization in the PARADIGM-HF trial of angiotensin receptor-neprilysin inhibitor vs. enalapril in HFrEF, systematically excluded patients with eGFR below 30 ml per minute per 1.73 m2 of body-surface area at screening or at the time of randomization [58, 59]. Therefore, the use of the new combination should be reserved for patients without advanced chronic kidney disease.

Role and the implications of diuretic therapy with concomitant ESRD:

Diuretic use has been shown to be low upon initiation of dialysis due to the belief that dialysis patients do not have significant urine volume [60]. Previous studies have shown that diuretics affect water and sodium excretion in patients with end stage renal disease but the effects on preserving residual renal volume in such patients is limited [61-64]. Presently, data is limited on role of diuretics in patients with heart failure and end stage renal disease.

8. ICD IN PATIENTS WITH CHRONIC SYSTOLIC HEART FAILURE AND ESRD

8.1. Transvenous Type

Survival is lower in patients with HF and ESRD and approximately of 20% patients die from SCD. This is compounded by the fact that prescription rates of ICD are reported to be lower due to lack of definitive evidence supporting their use in this group of patients [65]. In addition, randomized clinical trials that have shown the benefit of ICD in patients with heart failure with reduced ejection fraction have systematically excluded the ESRD patients [66, 67]. Some studies have shown that despite ICD use, mortality was still noted to be higher [68]. In analysis by Friedman et al. [69], dialysis patients with CRT were associated with increased risk of mortality and all-cause hospitalization and they were less likely to demonstrate echocardiographic response. It is important to note that although the overall outcome was not good, some patients had shown substantial echocardiographic response thereby suggesting some role in this highly comorbid patients. Also, patient did not experience any procedure related complications. In a meta-analysis by Chen et al. [10], the use of ICD was associated with overall survival and 2 year survival rate. The studies have shown a median survival of 1.1-3.2 years in ESRD patients with ICD. It is important to note that in patients with HF and on HD, use of ICD did not impact survival. In HD patients, the transvenous placement of CRT and other cardiac rhythm devices has been associated with an increased risk of device-related infections and central vein stenosis [70]. To avoid such risks, the use of an epicardial approach has recently been suggested for CRT devices in these patients, rather than the classical transvenous route [71].

8.2. Subcutaneous ICD

Recent analysis by El-Chami et al. has shown that in about 27 patients on chronic dialysis, use of SC ICD is associated with lower risk of infections when compared to transvenous ICD. In addition, patients were also noted to have lower incidence of inappropriate shocks [72].

8.3. Left Ventricular Assist Devices (LVADs) and ESRD

Patients with ESRD are rarely referred for LVAD implantation with only 1.5% of patients with new implants requiring dialysis before surgery based on data from the INTERMACS database [73]. The majority of patients with cardio-renal syndrome on renal replacement therapy (RRT) before LVAD implantation, show improvement of their renal function and are weaned off RRT [74, 75]. The remaining patients who continue to require RRT are either listed for heart and kidney transplantation or remain on LVAD support as Destination Therapy (DT). Limited data exists at this time about the role of LVAD in DT patients on RRT with most of the data limited to single center studies with very dismal outcomes. In one study, 1-year survival rate was reported to be 0% in 22 LVAD recipients who were on chronic HD without subsequent heart transplantation [76]. In a recent study by Bansal et al., patients with ESRD (median duration was 4 years) at the time of LVAD placement were noted to have extremely poor prognosis with most surviving for less than 3 weeks [77].

8.4. Practical Considerations

Patients with HFrEF and ESRD represent a subgroup of patients not adequately studied in large randomized trials of medical and device therapies. The rates of mortality and rehospitalization remain higher than those in the general HFrEF population. The first step in the management of these patients should include optimization of risk factors including obstructive coronary artery disease, severe valvular disease, uncontrolled hypertension, high output HF secondary to arterio-venous fistula and anemia (Fig. 1). Optimization of vol-
volume status is often challenging. These patients often develop intradialytic hypotension which limits volume removal and leads to interdialytic hypervolemia. Approaches to overcome these difficulties include: Careful assessment of volume status and target dry weight, dosing of beta blockers and ACE/ARBs on non-dialysis days, low sodium intake, use of cool dialysate solution to increase vascular resistance, and if the above fail, increase of dialysis time and frequency or even nocturnal dialysis. Since anemia is associated with increased mortality in HFrEF and a previous randomized controlled (FAIR-HF) showing symptomatic benefit from intravenous iron infusion in patients with ferritin<100 mcg/l or transferrin saturation <20% [78], intravenous iron supplementation may be beneficial to iron deficient patients with HFrEF and ESRD. Beta-blockers, preferably non-dialyzable such as carvedilol or bisoprolol, should be the first line treatment in these patients. In patients tolerating b-blockers, the addition of ACEI or ARBs with careful monitoring of serum potassium should be considered. These agents should be initiated at low doses and up-titrated slowly every two to four weeks to avoid hypotension and decompensation. In patients with HFrEF with NYHA II to IV symptoms that are intolerant to ACEI/ARBs, a combination of hydralazine plus nitrate could be used. The use of mineralocorticoid receptor antagonists, angiotensin receptor-neprilysin inhibitors and ivabradine is controversial and cannot be recommended until more data are available. Among devices therapies, ICDs and CRT should be implanted according to the standardized criteria. Finally, patients with refractory stage D HF should be evaluated for heart/kidney transplant listing.

CONCLUSION

Although, there is a growing population of patients with ESRD supported by LVADs as either bridge to transplant or DT, careful consideration of the risks is necessary before the evaluation for mechanical circulatory support. Better representation of these patients with HFrEF and ESRD in ongoing and future clinical trials will provide valuable evidence on the safety and efficacy of established and emerging medical and device therapies.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Genovesi S, Valsecchi MG, Rossi E, et al. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2529-36.
[2] Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dial 2008; 21: 300-7.
[3] Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 2000; 36: S24-30.
Therapeutic Approach to Patients with Heart Failure

Current Cardiology Reviews, 2018, Vol. 14, No. 1 65

[4] Harrett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-90.

[5] Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure. JAMA 1999; 282: 1834-40.

[6] Mogensen UM, Erboll M, Andersen M, et al. Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups. Eur J Heart Fail 2011; 13: 1216-23.

[7] Postmus D, van Veldhuisen DJ, Jaarsma T, et al. The COACH risk engine: A multistate model for predicting survival and hospitalization in patients with heart failure. Eur J Heart Fail 2012; 14: 168-75.

[8] Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998-1005.

[9] Remppis A, Ritz E. Cardiac problems in the dialysis patient: Beyond coronary disease. Semin Dial 2008; 21: 319-25.

[10] Chen TH, Wo HT, Chang PC, Wang CC, Wen MS, Chou CC. A meta-analysis of mortality in end-stage renal disease patients receiving implantable cardioverter defibrillators (ICDs). PLoS One 2014; 9: e94948.

[11] Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004; 13: 163-70.

[12] Foley RN, Parfrey PS, Harrett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal-disease therapy. Kidney Int 1995; 47: 186-92.

[13] Harrett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive-heart-failure in dialysis patients - prevalence, incidence, prognosis and risk-factors. Kidney Int 1995; 47: 884-90.

[14] Stack AG, Bloembergen WE. A cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients. Am J Kidney Dis 2001; 38: 992-1000.

[15] Schreiber BD. Congestive heart failure in patients with chronic kidney disease and on dialysis. Am J Med Sci 2003; 325: 179-93.

[16] Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: A systematic integrative review. Biomed Res Int 2014; 2014: 937398.

[17] Workgroup KD. K/DOQI clinical practice guide- lines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45: S1-153.

[18] Goldberg RJ, Ismailov RM, Patlolla V, Lessard D, Spencer FA. Therapies for acute heart failure in patients with reduced kidney function: A community-based perspective. Am J Kidney Dis 2008; 51: 594-602.

[19] Patel UD, Hernandez AF, Liang L, et al. Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With The Guidelines - Heart Failure Program study. Am Heart J 2008; 156: 674-81.

[20] Stack AG, Mohammed A, Hanley A, Mutwali A, Nguyen H. Survival trends of US dialysis patients with heart failure: 1995 to 2005. Clin J Am Soc Nephrol 2011; 6: 1822-9.

[21] Cice G, Di Benedetto A, DiSla S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56: 1701-8.

[22] Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41: 1438-44.

[23] Wang AW-M, Wang M, Lam CW-K, Chan IH-S, Lui S-F, Sanderson JE. Heart failure in long-term peritoneal dialysis patients: A 4-year prospective analysis. Clin J Am Soc Nephrol 2011; 6: 805-12.

[24] Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-9.

[25] Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients–beneficial effects of carvedilol: A double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37: 407-11.

[26] Weir MA, Dixon SN, Fleet JL, et al. beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2015; 26: 987-96.

[27] Tang CH, Wang CC, Chen TH, Hong CY, Sue YM. Prognostic benefits of carvedilol, bisoprolol, and metoprolol controlled release/extended release in hemodialysis patients with heart failure: A 10-year cohort. J Am Heart Assoc 2016; 5: pii: e005284.

[28] Pfeffer JM, Pfeffer MA. Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. Am J Med 1988; 84: 37-44.

[29] The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.

[30] The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.

[31] Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-40.

[32] Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010; 105: 30A-5A.

[33] Hebert LA. Optimizing ACE-inhibitor therapy for chronic kidney disease. N Engl J Med 2006; 354: 189-91.

[34] Dzau VJ, Colucci WS, Williams GH, Cushman F, Meggs L, Hollenberg NK. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980; 302: 1373-9.

[35] Ahmed A, Rich MW, Zile M, et al. Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease. Am J Med 2013; 126: 150-61.

[36] Zhang GH, Hou FF, Zhang X, Liu QF. Can angiotensin-converting enzyme inhibitor be used in chronic kidney disease patients with serum creatinine level greater than 266 micromol/L? Zhonghua Nei Ke Za Zhi 2005; 44: 592-6.

[37] Zannad F, Kessler M, Leheert P, et al. Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70: 1318-24.

[38] Chang TI, Shilane D, Brunelli SM, Cheung AK, Chertow GM, Winkelmayer WC. Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Am Heart J 2011; 162: 324-30.

[39] Berger AK, Duval S, Manske C, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007; 153: 1064-73.

[40] Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42: 201-8.

[41] Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023-9.

[42] McCullough PA, Sandberg KR, Yee J, Hudson MP. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst 2002; 3: 188-91.

[43] Cice G, Di Benedetto A, DiSla S, et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010; 56: 1701-8.

[44] Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-8.

[45] Rocha R, Chanter PN, Zuckerman A, Sier C, et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-7.

[46] Rocha R, Stier CT, Jr, Kifor I, et al. Aldosterone: A mediator of myoccardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-8.

[47] Bombaack AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Nephrology 2012; 6: 336-45.
Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-8.

Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-92.

Taheiri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009; 20: 392-7.

Taheiri S, Mortazavi M, Pourmoghadas A, Seyrafian S, Alipour Z, Karimi S. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 2012; 23: 507-12.

Chua D, Lo A, Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: Is it safe? Clin Cardiol 2010; 33: 604-8.

Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol 2010; 21: 1550-9.

Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376: 875-85.

Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol 2011; 151: 218-24.

Luca Di Lullo AB, Domenico Russo, Mario Cozzolino, Claudio Ronco, Alberto Santoboni, Giovanni Barbera. Ivabradine, heart failure and chronic kidney disease. Nephrol Point Care 2015; 1: e39-e43.

Kurpesa M, Trzos E, Wierzbowska-Drabik K, Rechciński T. Ivabradine as a heart rate-lowering agent in a patient with end-stage renal failure after heart transplantation. Kardiol Pol 2010; 68: 684-6.

Rodgers JE. Sutent/valsartan: The newest addition to the toolbox for guideline-directed medical therapy of heart failure. Am J Med 2017; 130: 635-9.

McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.

Bragg-Gresham JL, Fissell RB, Mason NA, et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 2007; 49: 426-31.

Shaft T, Jaar BG, Plantinga LC, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study. Am J Kidney Dis 2010; 56: 348-58.

Schmidt P, Loew D, Dycka J, et al. Comparison of the effects of mazolimine and furosemide in patients with end-stage renal failure on chronic dialysis. Eur J Clin Pharmacol 1981; 20: 23-6.

Vereerstraeten PJ, Dupuis F, Toussaint C. Effects of large doses of furosemide in end-stage chronic renal failure. Nephron 1975; 14: 333-8.

Sjolund J, Garcia Anton D, Bayes LY, Hoekstra T, Dekker FW, Munoz Mendoza J. Diuretics, limited ultrafiltration, and residual renal function in incident hemodialysis patients: A case series. Semin Dial 2016; 29: 410-5.

Sakhuja R, Keebler M, Lai T-S, Gavin CM, Thakur R, Bhatt DL. Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol 2009; 103: 735-41.

Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1533-40.

Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83.

Cannizzaro LA, Piccini JP, Patel UD, Hernandez AF. Device therapy in heart failure patients with chronic kidney disease. J Am Coll Cardiol 2011; 58: 889-96.

Friedman DJ, Upadhyay GA, Singal G, et al. Usefulness and consequences of cardiac resynchronization therapy in dialysis-dependent patients with heart failure. Am J Cardiol 2013; 112: 1625-31.

Opelioni O, Sakhuja A, Liu X, Tang WHW, Schold JD, Navaneethan SD. Outcomes of infected cardiovascular implantable devices in dialysis patients. Am J Nephrol 2014; 40: 280-7.

Asif A, Salman LH, Lopera GG, Carrillo RG. The dilemma of transvenous cardiac rhythm devices in hemodialysis patients: Time to consider the epicardial approach? Kidney Int 2011; 79: 1267-9.

El-Chami MF, Levy M, Kelli HM, et al. Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on dialysis. J Cardiovasc Electrophysiol 2015; 26(8): 900-4.

Kirklin JK, Nafiel DC, Pagani FD, et al. Sixth INTERMACS annual report: A 10,000-patient database. J Heart Lung Transplant 2014; 33: 555-64.

Hasin T, Topilsky Y, Schirger JA, et al. Changes in renal function after implantation of continuous-flow left ventricular assist devices. J Am Coll Cardiol 2012; 59: 26-36.

Demirozu ZT, Etheridge WB, Radovancevic R, Frazier OH. Results of HeartMate II left ventricular assist device implantation on renal function in patients requiring post-implant renal replacement therapy. J Heart Lung Transplant 2011; 30: 182-7.

Patel AM, Eduardo Rame J, Rudnick MR. How does the nephrologist manage an LVAD patient on chronic maintenance dialysis? Semin Dial 2014; 27: 284-8.

Bansal N, Hailpern SM, Katz R, et al. Outcomes associated with left ventricular assist devices among recipients with and without end-stage renal disease. JAMA Intern Med 2017. [Epub ahead of print].

Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-48.